Follows liver fat and scarring in adults with type 2 diabetes over time
Checks how fatty liver disease changes over time in people with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study
Key facts
- Where
- Linköping, SwedenSee the site
Where in Sweden
- Department of Gastroenterology and Hepatology, Linköping University HospitalLinköping, SwedenNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Linkoeping University
- Trial code
- NCT07312136
- Record updated
- 9 October 2026
- Original description
The goal of this observational study is to understand how metabolic dysfunction-associated steatotic liver disease (MASLD) changes over time in individuals with type 2 diabetes who previously participated in the EPSONIP study.Read full original descriptionShow less
Evaluating the Prevalence and Severity of MASLD in Primary Care - a Follow-up Study
The goal of this observational study is to understand how metabolic dysfunction-associated steatotic liver disease (MASLD) changes over time in individuals with type 2 diabetes who previously participated in the EPSONIP study.
The main questions it aims to answer are:
1. How common are MASLD and advanced liver fibrosis at long-term follow-up? 2. Which factors are associated with progression or regression of liver fat accumulation and liver fibrosis over time?
Participants will:
* Undergo a clinical examination and review of medical history. * Provide blood, urine, and biobank samples. * Undergo liver assessment using vibration-controlled transient elastography (VCTE). * Undergo magnetic resonance imaging (MRI) to assess liver fat, liver fibrosis, and body composition. * Complete questionnaires regarding lifestyle and physical activity. * Undergo physical activity measurements using accelerometers and additional assessments related to blood pressure and sleep apnea.
Inclusion: Previously included and completed the assessments in the EPSONIP study (NCT03864510); Age >/= 18 years; Informed consent.
Exclusion: Liver transplantation; Other primary liver disease than MASLD diagnosed after inclusion in the EPSONIP study (NCT03864510); Contraindication to magnetic resonance imaging.